MRTX0902 is a highly effective SOS1:KRAS complex inhibitor that exhibits excellent brain penetration, high oral bioavailability, and strong selectivity. When combined with MRTX849 (1,2)-adagrasib (KRAZATI), it can significantly enhance its anti-tumor activity.
